Evidence map›Paper›PMID 39412402›Full record

ArticleJournal of the American Chemical Society2024

A Divergent Synthesis of Numerous Pyrroloiminoquinone Alkaloids Identifies Promising Antiprotozoal Agents.

Griffin L Barnes, Nicholas L Magann, Daniele Perrotta, Fabian M Hörmann, Sebastian Fernandez, Pratap Vydyam, Jae-Yeon Choi, Jacques Prudhomme, Armund Neal, Karine G Le Roch and 2 more

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Marine natural products.Natural product reports · 2026
    Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Griffin L BarnesDepartment of Chemistry, 1102 Natural Sciences II, University of California, Irvine, California 92697, United States.
Nicholas L MagannDepartment of Chemistry, 1102 Natural Sciences II, University of California, Irvine, California 92697, United States.
Daniele PerrottaDepartment of Chemistry, 1102 Natural Sciences II, University of California, Irvine, California 92697, United States.
Fabian M HörmannDepartment of Chemistry, 1102 Natural Sciences II, University of California, Irvine, California 92697, United States.
Sebastian FernandezDepartment of Chemistry, 1102 Natural Sciences II, University of California, Irvine, California 92697, United States.
Pratap VydyamDepartment of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut 06520, United States.ORCID 0000-0003-4944-6006
Jae-Yeon ChoiDepartment of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut 06520, United States.
Jacques PrudhommeDepartment of Molecular, Cell and Systems Biology, University of California, Riverside, Riverside, California 92521, United States.
Armund NealDepartment of Molecular, Cell and Systems Biology, University of California, Riverside, Riverside, California 92521, United States.
Karine G Le RochDepartment of Molecular, Cell and Systems Biology, University of California, Riverside, Riverside, California 92521, United States.
Choukri Ben MamounDepartment of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut 06520, United States.
Christopher D VanderwalDepartment of Chemistry, 1102 Natural Sciences II, University of California, Irvine, California 92697, United States.ORCID 0000-0001-7218-4521

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
Fosinopril analogs for the treatment of human babesiosisR01AI153100 · NIAID · YALE UNIVERSITY · PI BEN MAMOUN, CHOUKRI · 2021 to 2025
$3.6M
Hit-to-Lead Development of the Kalihinol Scaffold for Malaria TreatmentR01AI138139 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BEN MAMOUN, CHOUKRI, LE ROCH, KARINE GAELLE · 2018 to 2022
$3.6M
Development of endochin-like quinolones for babesiosis therapyR01AI123321 · NIAID · YALE UNIVERSITY · PI BEN MAMOUN, CHOUKRI · 2017 to 2020
$2.7M
Antigen Discovery and Vaccine Development for Human Babesia ParasitesR01AI152220 · NIAID · YALE UNIVERSITY · PI BEN MAMOUN, CHOUKRI · 2020 to 2024
$2.1M
An antigen-detection assay to diagnose Babesia microti infectionR44AI136118 · NIAID · L2 DIAGNOSTICS, LLC · PI LEDIZET, MICHEL · 2020 to 2022
$2.1M
An antigen-detection assay to diagnose Babesia microti infectionR43AI136118 · NIAID · L2 DIAGNOSTICS, LLC · PI LEDIZET, MICHEL · 2018 to 2018
$300k
NCI NIH HHS P30 CA062203NIAID NIH HHS R01 AI123321NIAID NIH HHS R01 AI138139NIAID NIH HHS R01 AI152220NIAID NIH HHS R01 AI153100NIAID NIH HHS R43 AI136118NIAID NIH HHS R44 AI136118
6 · The paper itself

Abstract

On the basis of a streamlined route to the pyrroloiminoquinone (PIQ) core, we made 16 natural products spread across four classes of biosynthetically related alkaloid natural products, and multiple structural analogs, all in ≤8 steps longest linear sequence (LLS). The strategy features a Larock indole synthesis as the key operation in a five-step synthesis of a key methoxy-PIQ intermediate. Critically, this compound was readily diverged via selective methylation of either (or both) of the imine-like or pyrrole nitrogens, which then permitted further divergence by either

Indexed as

AlkaloidsAntiprotozoal AgentsPlasmodium falciparumPyrroloiminoquinonesAntimalarialsHumansMolecular StructureParasitic Sensitivity TestsPyrrolesStructure-Activity RelationshipAlkaloidsAntimalarialsAntiprotozoal AgentsPyrrolesPyrroloiminoquinones

Identifiers

PMID39412402
PMCPMC11528414

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.